Biotech Stock News (ACAD) (RXII) (REGN) (AZN) (ZSPH)

Acadia Pharmaceuticals (NASDAQ:ACAD) On November 3, 2015 Acadia had announced that the FDA had given its Parkinson’s Drug, NUPLAZID, FDA priority review. To understand what this means, we must first understand what the FDA priority review actually means? A company is only given FDA priority review if the drug it has developed treats an unmet … Read more